» Articles » PMID: 25355710

Afrezza Inhaled Insulin: the Fastest-acting FDA-approved Insulin on the Market Has Favorable Properties

Overview
Specialty Endocrinology
Date 2014 Oct 31
PMID 25355710
Citations 17
Authors
Affiliations
Soon will be listed here.
Citing Articles

Principles and Therapeutics of .

Priya S, Rao P, Padmanabhan V, Chaitanya N J Pharm Bioallied Sci. 2025; 16(Suppl 5):S4271-S4283.

PMID: 40061654 PMC: 11888702. DOI: 10.4103/jpbs.jpbs_835_24.


A Comprehensive Analysis of Biopharmaceutical Products Listed in the FDA's Purple Book.

Chen F, Zhong H, Chan G, Ouyang D AAPS PharmSciTech. 2024; 25(5):88.

PMID: 38637407 DOI: 10.1208/s12249-024-02802-0.


Diabetes Technology Meeting 2023.

Tian T, Aaron R, DuNova A, Jendle J, Kerr D, Cengiz E J Diabetes Sci Technol. 2024; 18(5):1208-1244.

PMID: 38528741 PMC: 11418435. DOI: 10.1177/19322968241235205.


Microfluidic-based systems for the management of diabetes.

Zhang S, Staples A Drug Deliv Transl Res. 2024; 14(11):2989-3008.

PMID: 38509342 PMC: 11445324. DOI: 10.1007/s13346-024-01569-y.


Towards More Precise Targeting of Inhaled Aerosols to Different Areas of the Respiratory System.

Sosnowski T Pharmaceutics. 2024; 16(1).

PMID: 38258107 PMC: 10818612. DOI: 10.3390/pharmaceutics16010097.


References
1.
Rosenstock J, Lorber D, Gnudi L, Howard C, Bilheimer D, Chang P . Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010; 375(9733):2244-53. DOI: 10.1016/S0140-6736(10)60632-0. View